排序方式: 共有1条查询结果,搜索用时 250 毫秒
1
1.
Barouch DH Liu J Li H Maxfield LF Abbink P Lynch DM Iampietro MJ SanMiguel A Seaman MS Ferrari G Forthal DN Ourmanov I Hirsch VM Carville A Mansfield KG Stablein D Pau MG Schuitemaker H Sadoff JC Billings EA Rao M Robb ML Kim JH Marovich MA Goudsmit J Michael NL 《Nature》2012,482(7383):89-93
Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have typically shown post-infection virological control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges. Here we demonstrate vaccine protection against acquisition of fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus monkeys. Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIV(SME543) Gag, Pol and Env antigens resulted in an 80% or greater reduction in the per-exposure probability of infection against repetitive, intrarectal SIV(MAC251) challenges in rhesus monkeys. Protection against acquisition of infection showed distinct immunological correlates compared with post-infection virological control and required the inclusion of Env in the vaccine regimen. These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys. 相似文献
1